Research Article

Urea-to-Albumin Ratio and In-Hospital Mortality in Severe Pneumonia Patients

Yu Tian,1 Yihao Li,2 Zixin Jiang,1 and Jieru Chen1

1Department of Intensive Care Unit, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China
2Department of Anesthesiology, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China

Correspondence should be addressed to Zixin Jiang; 147533981@qq.com and Jieru Chen; chenjieru77@163.com

Received 20 June 2021; Accepted 29 September 2021; Published 22 October 2021

Academic Editor: Mohammad Sistanizad

Copyright © 2021 Yu Tian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. The urea-to-albumin ratio (UAR), as a new marker of the systemic inflammatory response, is associated with the mortality in pneumonia patients. However, the association between the UAR and in-hospital mortality in severe pneumonia (SP) has received little attention. Methods. In this single-center retrospective cohort study, 212 SP patients in intensive care unit (ICU) from June 1, 2016, to June 1st, 2020, with baseline UAR were enrolled. The primary outcome was in-hospital mortality. The association of UAR with in-hospital mortality was assessed using a multivariable-adjusted Cox model. Results. Of 212 patients, the median age was 73.0 (61.0, 82.8) years, 70.8% of patients were male, and the APACHE II score was 20.0 (16.0, 26.0). During the hospital period, 101 (47.6%) patients died. In-hospital mortality rates for the lower and higher UAR were 16 (27.6%) and 85 (55.2%), respectively \( ( P < 0.001) \). Kaplan–Meier analysis revealed that survival rates were significantly different between the two groups \( ( \text{log rank} = 13.71, \ P < 0.001) \). After adjusted for confounding factors, the higher UAR group was significantly associated with a hazard ratio (HR) for in-hospital mortality of 2.234 (95% confidence interval: 1.146–4.356, \( P = 0.018 \)). Besides, this pattern persisted in subgroup analyses considering sex \( ( \text{HR} = 9.380; 95\% \text{CI: 2.248–39.138; } P = 0.002) \). Conclusions. Higher UAR levels at the commencement of admission to ICU may be independently associated with increased in-hospital mortality in SP patients.

1. Introduction

Severe pneumonia (SP) in ICU patients represents a major concern for physicians because of the high mortality and morbidity rate attributable to these episodes [1–3]. Both community-acquired pneumonia or nosocomial pneumonia can progress to SP, which is associated with a mortality rate of more than 50% [4]. During the past decades, many strategies have been implemented with the aim to predict pneumonia severity and prognosis.

Urea-to-albumin ratio (UAR) is a new, inexpensive, and reproducible maker of systemic inflammatory responses that are suitable for routine use and can be easily calculated and determined under simple laboratory conditions. Previous studies reported that a high blood urea nitrogen-to-albumin ratio (B/A) is relevant to critical illness [5]. Risk factors for poor outcomes in patients with CAP include higher blood urea nitrogen and lower albumin [6–10]. B/A levels have also been reported to be associated with a high risk of 30-day mortality in ventilator-associated pneumonia (VAP) patients [11]. Moreover, Mahmood Y et al. applied elevated urea and decreased albumin to COVID-19 pneumonia patients to predict the admission to ICU [5]. However, there is no study on SP patients.

Therefore, in the present study, we aim to assess the association between UAR and in-hospital mortality in SP patients.

2. Materials and Methods

2.1. Study Design and Population. In this retrospective and cohort study, we enrolled the SP patients between June 1st, 2016, and June 1st, 2020, in the ICU of the Second Affiliated Hospital of Guangzhou Medical University after obtaining institutional approval. Written informed consent was approved by the retrospective nature. Patients who were
admitted to ICU were screened and, if eligible, were included. We screened the patients 18 years of age or older who were admitted to the ICU for SP. Patients were excluded for the reasons: (1) ICU duration <24 h, (2) end-stage renal failure (on dialysis), and (3) chronic liver disease. The end-stage renal failure, also known as end-stage renal disease (ESRD), is defined as requiring renal replacement therapy according to kidney disease improving global outcomes (KDIGO) guidelines. Chronic liver disease was defined as one of the following conditions: chronic HBV infection, chronic HCV infection, alcoholic liver disease, nonalcoholic fatty liver disease, and liver cirrhosis due to any cause [12].

2.2. Definitions. To confirm the reported clinical SP, the events were defined in a standardized approach with the use of criteria from the guidelines of SP in China (2016 version). Pneumonia was diagnosed when met one of the four criteria and criteria 5: (1) new cough or the ordinary respiratory disease worsened, with sputum and/or chest pain or not, (2) fever, (3) pulmonary moist rale and/or consolidation, (4) peripheral blood leucocyte count >10 × 10⁹/L or < 4 × 10⁹/L with a nuclear shift to the left or not, and (5) new chest radiographic infiltrate with pleural effusion or not and less possibility of alternative diagnoses. Pneumonia patients were diagnosed with SP when met one of the major criteria or three of the minor criteria. The major criteria include the following: (1) invasive mechanical ventilation and (2) septic shock needing vasopressors. The minor ones are as follows: (1) respiratory rate ≥ 30 breaths/min, (2) multilobar infiltrates, (3) PaO₂/FiO₂ ratio ≤ 250, (4) uremia (BUN level > 20 mg/dL), (5) confusion/disorientation, (6) leukopenia (WBC count < 4 × 10⁹/L), (7) thrombocytopenia (platelet count < 100 × 10⁹/L), (8) hypothermia (core temperature < 36°C), and (9) hypotension requiring massive fluid resuscitation.

2.3. Data Collection and Outcome. Baseline demographic data included age, sex, hospital-acquired pneumonia (HAP), hypertension, chronic heart disease, diabetes mellitus, stroke, chronic obstructive pulmonary disease, and chronic kidney disease. Clinical and biochemical data at the initial admission to ICU included mean arterial blood pressure (MAP), heart rate (HR), respiratory rate (RR), acute physiology and chronic health evaluation II (APACHE II) score, alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine, urea, albumin, white blood cell (WBC), neutrophil count, lymphocyte count, monocyte count, platelet count, red blood cell (RBC), hemoglobin, and hematocrit (HCT). Samples of peripheral blood were stored by tubes with ethylenediamine tetraacetic acid. Primary outcome was in-hospital mortality.

2.4. Statistical Analyses. Eligible patients were divided into two groups (UAR ≤ 0.2555 group and UAR > 0.2555 group) by the optimal value of UAR for predicting in-hospital mortality. The receiver operating characteristic (ROC) curve was used to examine the predictive power of UAR and to acquire UAR cutoff values to maximize sensitivity and specificity. Data were expressed as percentages, mean ± standard deviation, median (25–75th percentile). Independent two-group comparisons were performed using the Student t-test or Mann-Whitney U test for continuous data and chi-square test or Fisher’s exact test for categorical data. The cumulative incidence of survival was estimated by using the Kaplan–Meier curve, and differences were compared with the log rank test. The associations between UAR and the primary outcome were evaluated by Cox proportional hazards regression. A univariate Cox regression analysis was conducted to test the correlation between patients’ characteristics and in-hospital mortality. Then, the multivariate Cox regression was conducted to evaluate variables significantly associated with the primary outcome, which adjusted for covariates (P < 0.05 in univariate Cox analysis or clinical concern (sex)). Moreover, a formal test of interaction between UAR and sex was performed. In Cox models, time at risk was from the study entry until death during hospitalization, transfer, or discharge. The data missing under 5% were replaced by the mean or median. Statistical analyses were performed with SPSS, version 22.0. A value of P < 0.05 was considered statistically significant. Figures were conducted using GraphPad Prism Software 9.0.

3. Results

3.1. Baseline Characters. From 1st June 2016 to 30th June 2020, a total of 227 SP patients were screened in the ICU, of whom 2 patients whose ICU stay times were less than 24 hours, 2 patients who were at the end stage of renal failure (on dialysis), and 11 patients who have chronic liver disease. The remaining 212 patients with UAR values measured at baseline were eventually enrolled in the study (Figure 1). Baseline characteristics of these patients, categorized based on the optimal value of UAR for predicting in-hospital mortality, are given in Table 1. Of these 212 cases, the median age was 73.0 (61.0, 82.8), 70.8% of the patients were male, and 16.0% were hospital-acquired pneumonia. The median APACHE II score was 20.0 (16.0, 26.0) within the 24 hours after ICU admission. The baseline characteristics were compared between the higher and lower UAR groups. Patients in the higher UAR group were older (P = 0.001), were more likely to be male (P = 0.017), and had a higher APACHE II score (P < 0.001) than those in the lower UAR group. The radiological findings showed that 82.5% of the patients had bilateral pneumonia and 31.1% had pleural effusion. No significant difference in the radiological findings was observed (P = 0.389; P = 0.494, respectively).

3.2. Risk Factors for In-Hospital Mortality. All significant factors identified as predictors of in-hospital mortality (P < 0.05 in the Cox univariate regression analysis and clinical concern (sex)) are given in Table 2. Then, multivariate Cox analyses identified two prognostic factors for in-hospital mortality, including vasopressor use and CRRT (P = 0.004; P = 0.041; respectively).
Table 1: Comparison of baseline characteristics.

| Variables                        | Total (n = 212) | UAR ≤ 0.2555 (n = 58) | UAR > 0.2555 (n = 154) | P value |
|----------------------------------|-----------------|------------------------|-------------------------|---------|
| **Demographic data**             |                 |                        |                         |         |
| Age (years)                      | 73.0 (61.0, 82.8) | 66.0 (53.8, 78.3)      | 78.5 (63.0, 84.0)       | 0.001   |
| Sex (male)                       | 150, 70.8%      | 34, 13.8%              | 116, 46.3%              | 0.017   |
| **HAP**                          | 34, 16.0%       | 8, 13.8%               | 26, 16.9%               | 0.585   |
| **Underlying diseases**          |                 |                        |                         |         |
| Hypertension                     | 119, 56.1%      | 21, 36.2%              | 98, 63.6%               | <0.001  |
| Diabetes mellitus                | 53, 25.0%       | 10, 17.2%              | 43, 27.9%               | 0.109   |
| CHD                              | 25, 11.8%       | 4, 6.9%                | 21, 13.6%               | 0.175   |
| Stroke                           | 44, 20.8%       | 8, 13.8%               | 36, 23.4%               | 0.125   |
| COPD                             | 27, 12.7%       | 4, 6.9%                | 23, 14.9%               | 0.118   |
| CKD                              | 27, 12.7%       | 1, 1.7%                | 26, 16.9%               | 0.003   |
| **Radiological findings**        |                 |                        |                         |         |
| Bilateral pneumonia              | 175, 82.5%      | 50, 86.2%              | 125, 81.2%              | 0.389   |
| Pleural effusion                 | 66, 31.1%       | 16, 27.6%              | 50, 32.5%               | 0.494   |
| **Treatment**                    |                 |                        |                         |         |
| Invasive mechanical use          | 109, 51.4%      | 34, 13.8%              | 75, 48.7%               | 0.294   |
| Vasopressor use                  | 73, 34.4%       | 14, 24.1%              | 59, 38.3%               | 0.053   |
| CRRT                             | 73, 34.4%       | 7, 12.1%               | 66, 42.9%               | <0.001  |
| **Clinical data**                |                 |                        |                         |         |
| MAP (mmHg)                       | 83.0 (69.5, 103.0) | 85.0 (74.6, 108.5)     | 83.0 (66.9, 101.3)      | 0.153   |
| Heart rate (rate/min)            | 109.9 (83.8, 136.0) | 104.5 (84.4, 124.6)    | 111.9 (84.1, 139.7)     | 0.035   |
| Respiratory rate (rate/min)      | 27.0 (22.0, 34.8) | 25.5 (20.0, 33.3)      | 27.0 (22.0, 35.0)       | 0.161   |
| APACHE II score                  | 20.0 (16.0, 26.0) | 16.5 (12.0, 20.0)      | 22.0 (17.0, 27.3)       | <0.001  |
| **Laboratory results**           |                 |                        |                         |         |
| ALT (U/L)                        | 34.5 (21.0, 65.8) | 33.0 (21.0, 51.3)      | 34.8 (21.0, 76.8)       | 0.265   |
| AST (U/L)                        | 44.5 (27.0, 82.0) | 42.5 (24.5, 60.8)      | 44.5 (28.0, 97.0)       | 0.054   |
| Creatinine (umol/L)              | 114.9 (72.8, 191.4) | 65.2 (51.1, 85.6)      | 140.4 (98.0, 239.0)     | <0.001  |
| Urea (mmol/L)                    | 11.8 (6.9, 19.1) | 5.5 (4.2, 6.5)         | 15.4 (11.1, 21.6)       | <0.001  |
| Albumin (g/L)                    | 29.0 (24.1, 33.9) | 30.8 (26.5, 35.1)      | 28.3 (23.3, 33.3)       | 0.001   |
| WBC (10^9/L)                     | 11.7 (8.0, 16.0) | 12.9 (9.9, 16.8)       | 11.2 (6.8, 15.5)        | 0.035   |
| Neutrophil count (10^5/L)        | 10.0 (6.3, 20.0) | 10.0 (8.4, 14.6)       | 9.7 (5.7, 13.8)         | 0.072   |
| Lymphocyte count (10^5/L)        | 0.6 (0.3, 1.0)   | 0.8 (0.4, 1.3)         | 0.6 (0.3, 0.9)          | 0.006   |
| Monocyte count (10^9/L)           | 0.5 (0.2, 0.8) | 0.6 (0.3, 0.8)         | 0.5 (0.2, 0.8)          | 0.008   |
| Platelet count (10^5/L)          | 205.0 (117.3, 280.5) | 234.5 (176.8, 322.0) | 186.5 (98.3, 256.0)     | <0.001  |
| RBC (10^12/L)                    | 3.6 (2.6, 4.6) | 4.0 (3.1, 4.9)         | 3.4 (2.4, 4.4)          | <0.001  |
| Hemoglobin (g/L)                 | 102.9 (73.8, 132.0) | 112.9 (89.2, 136.6)   | 99.1 (69.0, 129.2)      | 0.001   |
| HCT (%)                          | 31.3 (22.7, 39.9) | 33.9 (26.6, 41.2)      | 30.3 (21.4, 39.2)       | 0.004   |
| **Clinical outcomes**            |                 |                        |                         |         |
| ICU LOS (days)                   | 12.0 (6.3, 21.0) | 14.0 (9.0, 24.3)       | 11.0 (5.0, 19.3)        | 0.020   |
| Hospital LOS (days)              | 21.0 (11.3, 32.0) | 25.0 (15.5, 36.3)      | 18.0 (10.0, 32.0)       | 0.040   |
| In-hospital death                | 101, 47.6%      | 16, 27.6%              | 85, 55.2%               | <0.001  |

Data are mean ± standard or medians (25th–75th percentile) or number and percentage. UAR, urea-to-albumin ratio; HAP, hospital-acquired pneumonia; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; CRRT, continuous renal replacement therapy; MAP, mean arterial pressure; APACHE, acute physiology and chronic health evaluation; ALT, alanine aminotransferase; AST, aspartate aminotransferase; WBC, white blood cell; RBC, red blood cell; HCT, hematocrit; LOS, length of stay.

Figure 1: Study algorithm, including patient enrollment and outcomes. Note: low group: UAR ≤ 0.2555; high group: UAR > 0.2555; SP: severe pneumonia; ROC: receiver operating characteristics curve.
3.3. Performance of Baseline UAR as a Predictor of In-Hospital Mortality by ROC Curve Analysis. The results of ROC analysis for UAR in predicting in-hospital mortality are shown in Figure 2. It suggested that UAR had a modest power for predicting in-hospital mortality (AUC = 0.63; 95% CI: 0.55–0.70; \( P < 0.001 \)). The optimal cutoff value of the UAR for predicting in-hospital mortality was 0.2555 (sensitivity 84.2%; specificity 37.8%).

3.4. UAR Associated with In-Hospital Mortality. During follow-up, 101 (47.6%) patients died during the hospitalization. The in-hospital mortality rates for the lower and higher UAR were 27.6% and 55.2%, respectively (Table 1). There were significant differences in the in-hospital mortality rates between the two groups (\( P < 0.001 \)). The Kaplan–Meier estimates of the in-hospital mortality for patients with different UAR values are shown in Figure 3. The Kaplan–Meier estimates revealed that the higher UAR group had higher in-hospital mortality rate than the lower group (log rank = 13.71, \( P < 0.001 \)).

To elucidate the specific relationship between UAR and in-hospital mortality, we used different models (Table 3, UAR \( \leq 0.2555 \) as the reference group). Crude Cox model analysis showed that an increased UAR was a significant predictor of in-hospital mortality (HR = 2.788; 95% CI: 1.577–4.929; \( P < 0.001 \); model 1). In model 3, after adjusted for age, sex, invasive mechanical ventilation, CRRT, vasopressor use, creatinine, alanine aminotransferase, and aspartate aminotransferase, an increased UAR was still an independent predictor of in-hospital mortality (HR = 2.234; 95% CI: 1.146–4.356; \( P = 0.018 \)).

3.5. Relationship between Mortality and UAR in the Sex Subgroup. Results of interaction analysis between UAR and sex are given in Table 4. There was a significant interaction between UAR and sex on in-hospital mortality (\( \beta = 4.290; \ P = 0.004 \)). Thus, a sex-stratified analysis was conducted. In the female subgroup, Cox analysis showed a higher in-hospital mortality in the UAR > 0.2555 group, after adjusted for age, sex, invasive mechanical ventilation, CRRT, vasopressor use, creatinine, alanine aminotransferase, and aspartate aminotransferase (HR = 9.380; 95% CI: 2.248–39.138; \( P = 0.002 \)). However, this pattern was not observed in the male subgroup (\( P = 0.112 \)).

Table 2: Independent predictors of in-hospital mortality by univariate and multivariate Cox regression analyses.

| Factors | HR (95% CI) | \( P \) |
|---------|-------------|-------|
| Age     | 1.013 (1.001–1.026) | 0.029 |
| Mechanical ventilation | 0.796 (0.641–0.990) | 0.040 |
| Vasopressor use | 2.407 (1.619–3.578) | <0.001 |
| CRRT    | 2.402 (1.607–3.592) | <0.001 |
| ALT     | 1.001 (1.000–1.001) | 0.006 |
| Albumin | 0.947 (0.908–0.988) | 0.011 |
| Urea    | 1.020 (1.003–1.037) | 0.024 |
| AST     | 1.001 (1.000–1.001) | <0.001 |
| Creatinine | 1.002 (1.000–1.003) | 0.016 |

Multivariate Cox analysis

| Vasopressor use | 1.888 (1.226–2.907) | 0.004 |
| CRRT | 1.679 (1.020–2.762) | 0.041 |

Covariates included in multivariate analysis: age, sex, mechanical ventilation, vasopressor use, CRRT, ALT, albumin, urea, AST, creatinine. CRRT, continuous renal replacement treatment; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HR, hazard ratio; CI, confidence interval.

Figure 2: ROC curve for predicting mortality in patients with SP. UAR had a modest power for predicting in-hospital mortality as suggested by AUC of 0.63 (95% CI: 0.55–0.70; \( P = 0.001 \)), with a sensitivity of 84.2% and a specificity of 37.8% at a cutoff of 0.2555.

Figure 3: Kaplan–Meier survival curve according to the UAR level. Compared to the lower group (UAR \( \leq 0.2555 \)), patients in the higher group (UAR > 0.2555) showed elevated in-hospital mortality.
4. Discussion

Our results suggested that the first UAR values after admission to ICU were independently associated with an increased risk of in-hospital mortality in SP patients. Interestingly, this study found that similar trends were observed in the femalesubgroup, but not in males. Additionally, patients with higher baseline UAR values may be elderly and more likely to be male and have a higher APACHE II score.

SP, as a severe lung infection and inflammation, is still a common reason for ICU admission with a mortality rate of more than 50%. The UAR, novel inflammatory markers, reflect two pathways, which are probably less affected by confounding conditions and may be more predictive in evaluating the prognosis of pneumonia than urea or albumin separately [13]. Besides, as a simple and objective severity indicator for pneumonia, UAR is easy to implement in routine clinical practice when compared with the pneumonia severity index (PSI) and the CURB-65 score for pneumonia severity [14]. The performance of predictive function about UAR, PSI, and the CURB-65 score was not significantly different [15].

Study has shown that higher urea and lower albumin indicated worse clinical outcome in CAP patients [6–10]. Ujagin et al. revealed that the blood urea nitrogen/serum albumin (B/A) ratio performed well for predicting mortality and severity of CAP [16]. Feng et al.’s study showed that the B/A ratio was associated with poorer survival outcomes in 30-day ventilation-acquired pneumonia (VAP). An earlier study calculated the optimal cutoff point of B/A values for 30-day mortality using ROC curves in CAP patients. The point was at 0.165 [17]. Ryu et al. found that, in aspiration pneumonia patients, the AUC for B/A ratio was at 0.70 for predicting mortality within 28 days [18]. However, very few studies in the literature have evaluated UAR as a predictor of worse outcomes in SP patients. Thus, according to the previous research studies, we speculate that the UAR may be an important indicator of mortality in SP patients. The results of our study were consistent with this speculation.

Our study included both CAP and HAP patients in the ICU. In our ROC curve analysis, we determined a cutoff value of 0.2555 for in-hospital mortality. Multivariable Cox regression identified that the higher UAR was significantly associated with an HR of 2.234 for in-hospital mortality even after adjusted for age, sex, invasive mechanical ventilation, CRRT, vasopressor use, creatinine, alanine aminotransferase, and aspartate aminotransferase. However, the underlying mechanism has remained unclear. Urea is a marker associated with systemic disease. High values of urea lead to high susceptibility to infection. Some previous studies suggested that urea affects the prognosis of critical patients regardless of the creatine level [19, 20]. In the predictive models, urea is a significant risk factor for pneumonia. Moreover, urea is an indirect marker of a metabolic systemic pathway [21]. In pneumonia patients, elevated values of serum urea are an indicator of protein catabolism. Additionally, water deficiency appears to be common in pneumonia patients. In the process of dehydration, the concentration of urea increased. Meanwhile, the effect of increased urea reabsorption in the kidney causes high urea concentration [18]. Finally, the urea level is regarded as a predictive marker reflecting the cumulative effects of hemodynamic damage, which is essential in critical illness.

Serum albumin plays a significant role in maintaining physiological homeostasis, including keeping a colloid osmotic pressure [22]. On the other hand, hypoalbuminemia can result in the pulmonary edema due to decreased colloid osmotic pressure which can result in mortality [23]. Xue et al. suggested that hypoalbuminemia in the early stage had a high incidence of infection and mortality [24]. At the same time, pneumonia is an inflammation with high catabolism condition. Systemic inflammatory response can decrease

| Table 3: Relationship between UAR level and in-hospital mortality. |
|--------------------------|--------------------------|--------------------------|
| In-hospital mortality     | HR (95%CI)               | P                        |
| Unadjusted               | 2.788 (1.577–4.929)      | <0.001                   |
| Model 1                  | 2.724 (1.499–4.949)      | 0.001                    |
| Model 2                  | 2.080 (1.100–3.934)      | 0.024                    |
| Model 3                  | 2.234 (1.146–4.356)      | 0.018                    |

Reference group is UAR ≤ 0.2555 group. Model 1: age and sex. Model 2: model 1 plus treatment (mechanical ventilation, CRRT, and vasopressor use). Model 3: model 2 plus and laboratory test (creatinine, ALT, and AST). CRRT, continuous renal replacement treatment; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HR, hazard ratio; CI, confidence interval.

| Table 4: Relationship between in-hospital mortality and UAR level by sex. |
|--------------------------|--------------------------|--------------------------|
| In-hospital mortality     | Male                     | Female                   | Sex*U/A interaction |
| HR (95% CI)               | P                        | HR (95% CI)              | P                        | β           | P                        |
| UAR                      | 0.520 (0.232–1.165)      | 0.112                    | 9.380 (2.248–39.138)     | 0.002       | 4.290                    | 0.004                    |

Adjusted for age, mechanical ventilation, CRRT, vasopressor use, ALT, AST, creatinine. CRRT, continuous renal replacement treatment; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HR, hazard ratio; CI, confidence interval.
serum albumin levels [22]. Clearly, hypoalbuminemia is often observed in malnutrition patients, resulting in worse outcomes. It is interesting to note that earlier studies mostly focused on CAP showed that nonsurvivors have significantly lower urea and higher albumin than those of survivors. The study reported before demonstrated that UAR is an independent marker of the severity of CAP and mortality [22]. Our findings are consistent with previous conclusions. Further subgroup analyses were conducted by Kaplan–Meier analysis. Another notable finding was that higher UAR were associated with a higher risk of cumulative in-hospital mortality in female patients. To the authors’ knowledge, this research may be the first time to reveal the association between UAR and in-hospital mortality in female patients. A previous study reported that males had a higher fractional synthesis rate of albumin than females regardless of age and protein intake. Males had higher albumin concentration than females [25]. Therefore, the increase of UAR in critical illness was not so obvious in males. Weaving et al. demonstrated that albumin values in females decreased more quickly [26]. This is owing to the different values of parameters between males and females. Our results are consistent with the previous studies. Further studies are needed to examine why UAR is associated with mortality in female patients.

Our research has some limitations. First, as a single-center retrospective study, it may contain bias and be insufficient to draw the same conclusion in other populations. Second, the samples were small, so the predictive value of the UAR needs to be further validated in other observational studies. Third, in the present study, we investigated only baseline variables rather than changes over time in these variables in SP patients who were admitted to the ICU. Besides, we did not detect different types of pneumonia and its relationship with the mortality. The next generation sequencing (NGS) test will be added in our future study for better verification of conclusion.

5. Conclusions

Our study demonstrated that UAR is an independent risk factor for in-hospital mortality in SP patients, especially in females. These findings suggested that the baseline UAR, a simple and widely available biomarker, could be useful for risk stratification of in-hospital mortality in SP patients. We found this conclusion in our preprint [27].

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Yu Tian and Yihao Li contributed equally to this work.

Acknowledgments

The authors express their gratitude to all patients who participated in the study.

References

[1] M. I. Restrepo, E. M. Mortensen, J. A. Velez, C. Frei, and A. Anzueto, “A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU,” *Chest*, vol. 133, no. 3, pp. 610–617, 2008.
[2] K. E. Kollef, G. E. Schramm, A. R. Wills, R. M. Reichley, S. T. Micek, and M. H. Kollef, “Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria,” *Chest*, vol. 134, no. 2, pp. 281–287, 2008.
[3] M. I. Restrepo and A. Anzueto, “Severe community-acquired pneumonia,” *Infectious Disease Clinics of North America*, vol. 23, no. 3, pp. 503–520, 2009.
[4] S. M. Brown and N. C. Dean, “Defining and predicting severe community-acquired pneumonia,” *Current Opinion in Infectious Diseases*, vol. 23, no. 2, pp. 158–164, 2010.
[5] M. Y. Hachim, I. Y. Hachim, K. B. Naem, H. Hannawi, I. A. Salmi, and S. Hannawi, “D-Dimer, troponin, and urea level at presentation with COVID-19 can predict ICU admission: a single centered study,” *Frontiers of Medicine*, vol. 7, Article ID 585003, 2020.
[6] K. F. Bodmann, “Current guidelines for the treatment of severe pneumonia and sepsis,” *Chemotherapy*, vol. 51, no. 5, pp. 227–233, 2005.
[7] W. S. Lim, M. M. van der Eerden, R. Laing et al., “Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study,” *Thorax*, vol. 58, no. 5, pp. 377–382, 2003.
[8] B. M. Farr, A. J. Sloman, and M. J. Fisch, “Predicting death in patients hospitalized for community-acquired pneumonia,” *Annals of Internal Medicine*, vol. 115, no. 6, pp. 428–436, 1991.
[9] R. Raz, P. Dyachenko, Y. Levy, E. Flatau, and N. Reichman, “A predictive model for the management of community-acquired pneumonia,” *Infection*, vol. 31, no. 1, pp. 3–8, 2003.
[10] P. D. Potgieter and J. M. J. Hammond, “The intensive care management, mortality and prognostic indicators in severe community-acquired pneumococcal pneumonia,” *Intensive Care Medicine*, vol. 22, no. 12, pp. 1301–1306, 1996.
[11] J. H. Lee, J. Kim, K. Kim et al., “Albumin and C-reactive protein have prognostic significance in patients with community-acquired pneumonia,” *Journal of Critical Care*, vol. 26, no. 3, pp. 287–294, 2011.
[12] L. Li, J. Zhou, X. Hao et al., “The incidence, risk factors and in-hospital mortality of acute kidney injury in patients after surgery for acute type A aortic dissection: a single-center retrospective analysis of 335 patients,” *Frontiers of Medicine*, vol. 7, Article ID 557044, 2020.
[13] Z. D. Dundar, K. Kucukceran, and M. K. Ayrancli, “Blood urea nitrogen to albumin ratio is a predictor of in-hospital mortality in older emergency department patients,” *The American Journal of Emergency Medicine*, vol. 46, pp. 349–354, 2021.
[14] A. Singanayagam, J. D. Chalmers, and A. T. Hill, “Severity assessment in community-acquired pneumonia: a review,” *QJM: Monthly Journal of the Association of Physicians*, vol. 102, no. 6, pp. 379–388, 2009.
[15] M. Ugajin, K. Yamaki, N. Hirase, T. Kobayashi, and T. Yagi, “Prognostic value of severity indicators of nursing-
home-acquired pneumonia versus community-acquired pneumonia in elderly patients,” Clinical Interventions in Aging, vol. 9, pp. 267–274, 2014.

[16] M. Ugajin, K. Yamaki, N. Hirasawa, and T. Yagi, “Predictive values of semi-quantitative procalcitonin test and common biomarkers for the clinical outcomes of community-acquired pneumonia,” Respiratory Care, vol. 59, no. 4, pp. 564–573, 2014.

[17] D.-Y. Feng, Y.-Q. Zhou, X.-L. Zou et al., “Elevated blood urea nitrogen-to-serum albumin ratio as a factor that negatively affects the mortality of patients with hospital-acquired pneumonia,” The Canadian Journal of Infectious Diseases & Medical Microbiology, vol. 2019, Article ID 1547405, 6 pages, 2019.

[18] S. Ryu, S. K. Oh, S. U. Cho et al., “Utility of the blood urea nitrogen to serum albumin ratio as a prognostic factor of mortality in aspiration pneumonia patients,” The American Journal of Emergency Medicine, vol. 43, pp. 175–179, 2021.

[19] M. J. Fine, T. E. Auble, D. M. Yealy et al., “A prediction rule to identify low-risk patients with community-acquired pneumonia,” New England Journal of Medicine, vol. 336, no. 4, pp. 243–250, 1997.

[20] D. Aronson, M. A. Mittleman, and A. J. Burger, “Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated heart failure,” The American Journal of Medicine, vol. 116, no. 7, pp. 466–473, 2004.

[21] D. H. Oh, Y. C. Kim, E. J. Kim et al., “Multidrug-resistant Acinetobacter baumannii infection in lung transplant recipients: risk factors and prognosis,” Infectious Diseases, vol. 51, no. 7, pp. 493–501, 2019.

[22] M. Ugajin, K. Yamaki, N. Iwamura, T. Yagi, and T. Asano, “Blood urea nitrogen to serum albumin ratio independently predicts mortality and severity of community-acquired pneumonia,” International Journal of General Medicine, vol. 5, pp. 583–589, 2012.

[23] T. B. Horwich, K. Kalantar-Zadeh, R. W. MacLellan, and G. C. Fonarow, “Albumin levels predict survival in patients with systolic heart failure,” American Heart Journal, vol. 155, no. 5, pp. 883–889, 2008.

[24] P. Xue, Z. W. Huang, Y. H. Li et al., “Clinical study on severe acute pancreatitis associated with hypoalbuminemia in early stage,” Zhong xi yi jie he xue buo = Journal of Chinese Integrative Medicine, vol. 3, no. 6, pp. 443–445, 2005.

[25] A. E. Thalacker-Mercer, C. A. Johnson, K. E. Yarasheski, N. S. Carnell, and W. W. Campbell, “Nutrient ingestion, protein intake, and sex, but not age, affect the albumin synthesis rate in humans,” Journal of Nutrition, vol. 137, no. 7, pp. 1734–1740, 2007.

[26] G. Weaving, G. F. Batstone, and R. G. Jones, “Age and sex variation in serum albumin concentration: an observational study,” Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, vol. 53, no. 1, pp. 106–111, 2016.

[27] Y. Tian, Y. Li, J. Chen, and Z. Jiang, “Urea to albumin ratio is an independent predictor of in-hospital mortality in patients with severe pneumonia: a retrospective cohort study,” Research Square, 2021.